MetaCap

Prothena Corporation plc (PRTA)

NASDAQ: PRTAHealth CareBiotechnology: Pharmaceutical PreparationsUSD

8.22-0.18 (-2.14%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

PRTA stock chart

Technical analysis

Key statistics

All statistics
Market cap
$422.10M
EPS (TTM)
-$0.45
52-week range
7.70 – 11.80
Day range
8.07 – 8.47
Volume / Avg
861.55K / 487.91K
Beta
—

52-week range

$7.70$11.80

PRTA stock today

Shares of Prothena (PRTA) finished lower on Nov 20 at $8.22, a drop of 2.14% or $0.18 per share, versus the S&P 500's 3.70% decline. Shares are 30.3% below their 52-week high of $11.80, set on May 8, 2026 and 6.8% above the 52-week low of $7.70, near the bottom of the past year's range. PRTA is down 13.9% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 21.6%.

Prothena has posted a net loss over the last twelve months (EPS of -$0.45), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Prothena

Company profile

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial for the treatment of transthyretin amyloidosis; BMS-986446, an anti-tau antibody which is in Phase 2 clinical trial to treat Alzheimer's disease; PRX019, an investigational antibody which is in Phase 1 clinical trial for the treatment of neurodegenerative diseases; and PRX123, a Dual Aß-Tau Vaccine, which is in preclinical trial for treating Alzheimer's disease.

Industry
Biotechnology: Pharmaceutical Preparations
CEO
Dr. Gene G. Kinney Ph.D.
Headquarters
Dublin
Employees
67

Financial highlights

Full financials

In fiscal 2025, Prothena generated $9.7 million in revenue, down 92.8% from fiscal 2024, its first annual decline since 2022. Prothena reported a net loss of $244.1 million, compared with a loss of $122.3 million a year earlier. Operating margin was -2216.4%.

Prothena annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$9.68M$135.16M$91.37M$53.91M$200.58M
Growth-92.83%+47.92%+69.50%-73.13%+23414.30%
Net income$-244.09M$-122.31M$-147.03M$-116.95M$66.97M
EPS (diluted)$-4.53$-2.27$-2.76$-2.47$1.38

Analyst forecast

Forecast

Consensus (7 analysts)

buy

Avg. price target

$21.40+160.34%

  • Strong buy 2
  • Buy 2
  • Hold 2
  • Sell 0
  • Strong sell 1

Target range

Low $8.00High $36.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 5, 2026
EPS actual vs est.
$-0.32 vs $-0.38
Surprise
+15.79%

PRTA news

All PRTA news

Prothena peers

Health Care sector
PRTA peer companies
CompanyPrice% ChgMarket capCompare
ARVNArvinas Inc.6.46-4.15%$423.03Mvs PRTA
CRMDCorMedix Inc.5.27+3.74%$419.16Mvs PRTA
OVIDOvid Therapeutics Inc.2.20-5.98%$415.21Mvs PRTA
EOLSEvolus Inc.6.52-6.86%$431.55Mvs PRTA
INDPIndaptus Therapeutics Inc.2.82-9.90%$433.16Mvs PRTA
AQSTAquestive Therapeutics Inc.3.46-6.61%$434.88Mvs PRTA
CAPRCapricor Therapeutics Inc.7.59+0.80%$441.30Mvs PRTA
LYELLyell Immunopharma Inc.13.80+1.62%$441.82Mvs PRTA

Indexes, lists and sector

Prothena stock FAQ

What is Prothena's stock price today?

PRTA last traded at $8.22 as of Nov 20, 4:00 PM EST, down 2.14% on the day. Prices are delayed at least 15 minutes.

Who is Prothena's CEO?

Dr. Gene G. Kinney Ph.D. is the chief executive officer of Prothena Corporation plc, which has about 67 employees.

What is the PRTA 52-week high?

The 52-week high for PRTA is $11.80 and the 52-week low is $7.70. The stock is currently 30.3% below its high.

Compare PRTA